Scholarlink

Background <p>Chronic kidney disease (CKD) affects approximately 10% of adults living in Germany. Patients with CKD are at increased risk of kidney failure and cardiovascular disease. The aim of this update is to align the guideline with current evidence to ensure the best possible care for people with CKD.</p> Search strategy <p>A&#xa0;search for updated international guidelines was conducted. The NICE (National Institute for Health and Care Excellence, 2021) guideline and the KDIGO (Kidney Disease: Improving Global Outcomes, 2023) guideline were identified as primary source guidelines. A&#xa0;comprehensive literature review was performed to guide recommendations on SGLT2 inhibitors. Agreement was reached on the recommendations and background texts in a&#xa0;structured consensus process.</p> New guideline recommendations <p>1)&#xa0;Check for albuminuria using the urine albumin–creatinine ratio (UACR) to recognize CKD early and stage CKD accurately; 2)&#xa0;Use risk scores such as the Kidney Failure Risk Equation (KFRE) to account for age and sex in the risk assessment; 3)&#xa0;Perform urinary tract ultrasound for all patients with suspected CKD; 4)&#xa0;Consider a&#xa0;SGLT2 inhibitor for patients with significant albuminuria or moderate renal impairment; 5)&#xa0;Do not treat asymptomatic hyperuricemia; 6)&#xa0;Standing Commission on Vaccination (STIKO) recommendations are now part of this guideline.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nicht-nierenersatztherapiepflichtige chronische Nierenkrankheit in der Hausarztpraxis – Update der DEGAM-Leitlinie

  • 期刊论文

  • 发表日期：

    2025年3月24日

查看全文
  • Martha Negnal,
  • Simone Kiel,
  • Sylvia Stracke,
  • Leonard Mathias,
  • Elizabeth Mathias,
  • Til Uebel,
  • Erika Baum,
  • Susanne Fleig,
  • Martin K. Kuhlmann,
  • Jan Galle,
  • Julia Weinmann-Menke,
  • Joachim Seffrin,
  • Thomas Weinreich,
  • Michael Daschner,
  • Maik Gollasch,
  • Ute Hoffmann,
  • Annette Diehl,
  • Jean-François Chenot

摘要

Background

Chronic kidney disease (CKD) affects approximately 10% of adults living in Germany. Patients with CKD are at increased risk of kidney failure and cardiovascular disease. The aim of this update is to align the guideline with current evidence to ensure the best possible care for people with CKD.

Search strategy

A search for updated international guidelines was conducted. The NICE (National Institute for Health and Care Excellence, 2021) guideline and the KDIGO (Kidney Disease: Improving Global Outcomes, 2023) guideline were identified as primary source guidelines. A comprehensive literature review was performed to guide recommendations on SGLT2 inhibitors. Agreement was reached on the recommendations and background texts in a structured consensus process.

New guideline recommendations

1) Check for albuminuria using the urine albumin–creatinine ratio (UACR) to recognize CKD early and stage CKD accurately; 2) Use risk scores such as the Kidney Failure Risk Equation (KFRE) to account for age and sex in the risk assessment; 3) Perform urinary tract ultrasound for all patients with suspected CKD; 4) Consider a SGLT2 inhibitor for patients with significant albuminuria or moderate renal impairment; 5) Do not treat asymptomatic hyperuricemia; 6) Standing Commission on Vaccination (STIKO) recommendations are now part of this guideline.